Skip to content
Open access

Tau isoform imbalance and aggregation are pathological hallmarks of X-linked dystonia-parkinsonism

Jul 2026 · medRxiv · 0 citations
Medicine

TL;DR

It is reported that X-linked Dystonia-Parkinsonism (XDP), caused by a non-coding retrotransposon-associated repeat insertion in TAF1, involves a significant imbalance of tau isoforms and the accumulation of hyperphosphorylated, four-repeat tau in the brain.

Abstract

Tauopathies encompass diverse neurodegenerative diseases unified by aberrant patterns of tau deposition in brain. Although most appear sporadic, some are linked to genetic etiologies that offer unique mechanistic insights. Here we report that X-linked Dystonia-Parkinsonism (XDP), caused by a non-coding retrotransposon-associated repeat insertion in TAF1, involves a significant imbalance of tau isoforms and the accumulation of hyperphosphorylated, four-repeat tau in the brain. In striatal tissue, both misfolded tau accumulation, predominantly in astrocytes, and MAPT exon 10 inclusion correlated with repeat length within the causal insertion. Transcriptomic profiling across brain regions revealed dysregulation of known tau-related pathways. Levels of phosphorylated tau181, glial fibrillary acidic protein, and neurofilament light chain were elevated in patient plasma and discriminated XDP from controls. These findings implicate defective tau proteostasis as a key pathogenic mechanism and position XDP as a genetic model for uncovering cellular drivers that may disrupt tau in other more common neurodegenerative diseases.

Read PDF

Similar papers

Review Open access Jul 2026

The molecular and genetic view of tauopathies: From structural polymorphism to systemic neurodegeneration

A holistic perspective is provided by synthesizing recent developments in the molecular and genetic architecture of tauopathies, particularly newly discovered genetic risk loci and cellular proteostasis mechanisms to analytically evaluate the diagnostic value of fluid biomarkers and current data on next-generation clin...

E. Ünal, S. Çomoğlu · 0 citations
Open access Aug 2026

A conserved serotonin receptor pathway is a druggable modifier of Tau pathology, neural circuit formation and neurodegeneration

A new Drosophila tauopathy model expressing eGFP-tagged human TauWT or the disease-associated TauP301L variant in the nervous system is established and 5-HT7R signaling is identified as a conserved and druggable modifier of Tau toxicity.

Mariana I. Tsap, Valeriya V. Navrotska, J. Labus et al. · 0 citations
Review Aug 2026

Tau dysfunction in alzheimer’s disease: molecular and cellular mechanisms, genetic modulation, and therapeutic perspectives

Findings support a model in which tau dysfunction results from the convergence of molecular aberrations and genetic susceptibility within a pathological network involving amyloid-β, neuroinflammation, and synaptic failure.

S. Sura, S. Jagadeesan, M. A. M. Moklas et al. · 0 citations
Open access Sep 2026

GWAS of Tau‐Neurodegeneration Mismatch Identifies New Risk Loci for Susceptibility to Tau

A genome‐wide association study of tau‐related neurodegeneration identified two novel genetic variants in the loci AKAP9 and STXBP6 leading to higher than expected regional neurodegeneration given the tau level.

F. Nabizadeh, Hanieh Mohamadi · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.